Patents by Inventor Emilia Pisani

Emilia Pisani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NANOPARTICLES LOADED WITH CHEMOTHERAPEUTIC ANTITUMORAL DRUG
    Publication number: 20170333341
    Abstract: The invention relates to new therapeutic approaches for treating cancer, in particular hepatocellular carcinoma, with Nanoparticles loaded with a chemotherapeutic antitumoral agent. In particular, it relates to the treatment of cancer by administration of said Nanoparticles by intravenous infusion for at least 2 hours in order to prevent toxicological side effects and increase the benefit/risk ratio of the treatment.
    Type: Application
    Filed: August 10, 2017
    Publication date: November 23, 2017
    Inventors: Emilia PISANI, Sophie LEBEL-BINAY, Valérie POLARD
  • Nanoparticles loaded with chemotherapeutic antitumoral drug
    Patent number: 9763874
    Abstract: The invention relates to new therapeutic approaches for treating cancer, in particular hepatocellular carcinoma, with Nanoparticules loaded with a chemotherapeutic antitumoral agent. In particular, it relates to the treatment of cancer by administration of said Nanoparticules by intravenous infusion for at least 2 hours in order to prevent toxicological side effects and increase the benefit/risk ratio of the treatment.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: September 19, 2017
    Assignee: Onxeo S.A.
    Inventors: Emilia Pisani, Sophie Lebel-Binay, Valérie Polard
  • NANOPARTICLES LOADED WITH CHEMOTHERAPEUTIC ANTITUMORAL DRUG
    Publication number: 20140024610
    Abstract: The invention relates to new therapeutic approaches for treating cancer, in particular hepatocellular carcinoma, with Nanoparticules loaded with a chemotherapeutic antitumoral agent. In particular, it relates to the treatment of cancer by administration of said Nanoparticules by intravenous infusion for at least 2 hours in order to prevent toxicological side effects and increase the benefit/risk ratio of the treatment.
    Type: Application
    Filed: March 30, 2012
    Publication date: January 23, 2014
    Applicant: BIOLLIANCE PHARMA
    Inventors: Emilia Pisani, Sophie Lebel-Binay, Valérie Polard